sensei(US:SNSE)2024-05-09 11:37Financial Performance - Sensei Biotherapeutics reported a net loss of $8.0 million for Q1 2024, a decrease from a net loss of $10.2 million in Q1 2023[11]. - Cash, cash equivalents, and marketable securities totaled $58.1 million as of March 31, 2024, down from $65.8 million as of December 31, 2023[8]. - Research and Development (R&D) expenses were $4.9 million for Q1 2024, compared to $5.2 million for Q1 2023, primarily due to lower manufacturing-related expenses[9]. - General and Administrative (G&A) expenses decreased to $3.8 million in Q1 2024 from $5.8 million in Q1 2023, mainly due to reduced costs for external professional services[10]. - The company has a cash runway extending into the fourth quarter of 2025, allowing for continued operational funding[7]. Clinical Trials - The company completed enrollment in the dose escalation portion of the SNS-101 Phase 1/2 clinical trial, with 16 patients in the monotherapy arm and 18 patients in the combination arm[4]. - No dose limiting toxicities were observed in either the monotherapy or combination arms of the clinical trial[6]. - Sensei expects to report initial data from the dose expansion cohorts and hold an end-of-Phase 1 meeting with the FDA by the end of 2024[6]. - Sensei plans to present topline clinical data from the SNS-101 trial at the 2024 ASCO Annual Meeting scheduled for June 1, 2024[6]. - The company is focusing on advancing patient enrollment in the dose expansion cohorts to optimize the Phase 2 trial design for SNS-101[3].